Compare Cassava Sciences Inc (FLNA) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Okta, Inc. — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Okta, Inc. trades at $149.73 (market cap $26.22B). The key difference: Okta, Inc. is far larger — about 493.4× Cassava Sciences Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | OKTA | |
|---|---|---|
Market Cap | $53.14M | $26.22B |
Sector | Health | Technology |
52-Week High | $4.64 | $154.62 |
52-Week Low | $1.09 | $62.93 |
Enterprise Value | -$33.43M | $24.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
OKTA trades at $150.97, down 2.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported revenue of $2.61B in 2025, achieving positive net income of $28M after years of losses, and has beaten earnings estimates for three consecutive quarters. Analyst consensus is strongly bullish with 72.55% buy ratings, though the stock trades above the consensus price target of $125.78.
The outlook for OKTA is positive due to robust revenue growth, improving profitability, and strong demand for AI-driven cybersecurity solutions. Key risks include high valuation multiples, intense competition, and sensitivity to enterprise IT spending cycles. The stock presents a growth opportunity but requires monitoring of execution and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
